One Shot Could Permanently Lower Your Cholesterol by 62%

Imagine never worrying about high cholesterol again after just one doctor's visit. Scientists are making that future possible with a gene-editing treatment that permanently lowers cholesterol levels, and early results are stunning doctors.

Two small clinical trials tested CRISPR gene-editing technology to turn off liver genes that make cholesterol build up in the blood. The results published in The New England Journal of Medicine show this could replace daily pills with a single infusion.

In the first trial, 35 people at risk for early heart disease received a drug called VERVE-102 that turns off the PCSK9 gene. This gene normally makes it harder for your body to clear bad cholesterol from your bloodstream. After one treatment with the highest dose, cholesterol levels dropped by 62%.

A second trial targeted a different gene called angiopoietin-like protein 3, which also raises cholesterol. Using an experimental tool called CTX310, researchers created a tiny genetic change that stopped the gene from working. Cholesterol and triglyceride levels fell nearly 50% within two weeks and stayed low for at least 60 days.

Neither study reported major side effects. The most common issue was a temporary increase in a liver enzyme suggesting minor, short-term liver stress.

"This is a permanent change," says Dr. Steven Nissen, study co-author and chairman of cardiovascular medicine at the Cleveland Clinic. "It's a one and done treatment. That's why it's so exciting."

The science behind this sounds futuristic, but it's already helping people with other conditions. CRISPR-Cas9 acts like molecular scissors, snipping DNA at precise locations and rewriting genetic instructions. Doctors already use it to treat sickle cell anemia.

Why This Inspires

Heart doctors are calling this approach "incredible" and "approaching magic" for people struggling with high cholesterol despite medication and lifestyle changes. Dr. Yu-Ming Ni, a cardiologist at MemorialCare Heart and Vascular Institute, says it could "permanently remove this as a risk factor for heart disease in one treatment."

The shift from daily pills to a single treatment could transform how millions of people manage their heart health. For people with genetically high cholesterol or those who don't respond well to medications, this offers real hope.

Both treatments are moving to larger phase 2 trials to test effectiveness in more people. Because CRISPR changes your DNA, the FDA requires 15 years of safety monitoring before approval, so this won't be available at your doctor's office tomorrow.

But the potential is undeniable. A world where heart disease becomes preventable with precision medicine is closer than ever.